Results of a survey of AAP members show that most US pediatricians bypass an ECG before starting children on stimulant medication for ADHD, opting for a routine cardiac history and physical examination instead. Find out how perceived barriers to cardiac screening influence clinical practice.
Evaluations for attention-deficit/hyperactivity disorder (ADHD) should begin in children at 4 years and continue until 18 years, which significantly expands the age range for recommended screening. Released at the American Academy of Pediatrics National Conference in Boston, Massachusetts, the clinical practice guidelines recommend behavioral interventions as the first-line treatment in preschool children. The guidelines also have some new suggestions related to methylphenidate treatment for children younger than 6 years.
Here?s some new information that can help when you?re determining whom to screen for attention-deficit/hyperactivity disorder: ADHD prevalence has increased to 10% for children with family income less than 100% of the poverty level and to 11% for those with family income between 100% and 199% of the poverty level compared with a 7% to 9% overall increase, according to a National Center for Health Statistics report. Read more to find out what other indicators were linked with above-average increases in the disorder?s prevalence.
Findings of a population-based cohort study indicate that a low Apgar score at 5 minutes in newborns is associated with a higher risk of attention-deficit/hyperactivity disorder (ADHD) in childhood.
Atomoxetine is well tolerated and reduces core attention-deficit/hyperactivity disorder (ADHD) symptoms in preschool children, according to a study reported in Pediatrics.
Two-thirds of children with attention-deficit/hyperactivity disorder (ADHD) have comorbid mental health or neurodevelopment disorders, according to a large survey reported online in Pediatrics.
A restricted elimination diet may be effective in reducing symptoms of attention-deficit/hyperactivity disorder (ADHD) in children, according to researchers from the Netherlands.
The care that children with attention-deficit/hyperactivity disorder (ADHD) receive under managed-care Medicaid programs has much room for improvement, a new study in the Journal of the American Academy of Child and Adolescent Psychiatry suggests.
Although the exact cause of attention-deficit/hyperactivity disorder (ADHD) has not yet been determined, a new study provides evidence that tobacco and lead exposure may increase a child's risk of developing the condition.
Pharmacotherapy, namely the stimulant medications methylphenidate (MPH) and amphetamine (MAS) and the nonstimulant medication atomoxetine (Strattera), is the recommended treatment for attention-deficit/hyperactivity disorder (ADHD).